KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Current Assets (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Current Assets for 17 consecutive years, with $2.9 billion as the latest value for Q4 2025.

  • Quarterly Current Assets fell 4.1% to $2.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, down 4.1% year-over-year, with the annual reading at $2.9 billion for FY2025, 4.1% down from the prior year.
  • Current Assets for Q4 2025 was $2.9 billion at Bio-Rad Laboratories, up from $2.8 billion in the prior quarter.
  • The five-year high for Current Assets was $3.3 billion in Q1 2022, with the low at $2.0 billion in Q4 2021.
  • Average Current Assets over 5 years is $2.9 billion, with a median of $3.1 billion recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 58.65% in 2022, then dropped 8.02% in 2025.
  • Over 5 years, Current Assets stood at $2.0 billion in 2021, then surged by 58.65% to $3.2 billion in 2022, then fell by 3.47% to $3.0 billion in 2023, then fell by 0.59% to $3.0 billion in 2024, then decreased by 4.1% to $2.9 billion in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $2.9 billion, $2.8 billion, and $2.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.